FEMASYS INC (FEMY) News

FEMASYS INC (FEMY): $2.00

-0.04 (-1.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter FEMY News Items

FEMY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FEMY News Highlights

  • FEMY's 30 day story count now stands at 3.
  • Over the past 24 days, the trend for FEMY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • ACRX, DOV and SST are the most mentioned tickers in articles about FEMY.

Latest FEMY News From Around the Web

Below are the latest news stories about Femasys Inc that investors may wish to consider to help them evaluate FEMY as an investment opportunity.

Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer

-- Seasoned financial executive with 25 years of experience leading public and private biotech companies throughout various stages -- ATLANTA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of Dov Elefant to chief financial officer (CFO), to be effective February 28,

Yahoo | February 24, 2022

AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of real-world data in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects with the use of sufentanil sublingual tablet (SST) for pain management.

Yahoo | February 1, 2022

When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven?

AcelRx Pharmaceuticals, Inc. ( NASDAQ:ACRX ) is possibly approaching a major achievement in its business, so we would...

Yahoo | January 31, 2022

Femasys Inc. Announces the Appointment of Wendy Perrow, Transformational Biotech Entrepreneur, as New Board Member

Industry leader Wendy Perrow brings decades of expertise in fundraising, global product launches and corporate strategy to the Femasys teamATLANTA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of a new board member, Wendy Perrow. Ms. Perrow brings decades of experi

Yahoo | January 20, 2022

Zacks Investment Research Downgrades Femasys (NASDAQ:FEMY) to Hold

Zacks Investment Research downgraded shares of Femasys (NASDAQ:FEMY) from a buy rating to a hold rating in a report issued on Monday morning, Zacks.com reports. According to Zacks, Femasys Inc.is a biomedical company focused on transforming womens healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The []

Transcript Daily | December 24, 2021

Femasys Inc. to Participate in Upcoming January Investor Conferences

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women''s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11 th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.

GlobeNewswire | December 23, 2021

Femasys (NASDAQ:FEMY) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Femasys (NASDAQ:FEMY) from a hold rating to a buy rating in a research note released on Friday morning, Zacks.com reports. They currently have $4.50 target price on the stock. According to Zacks, Femasys Inc.is a biomedical company focused on transforming womens healthcare by developing novel solutions as well as []

Transcript Daily | December 18, 2021

Buy - Femasys Inc.''s Lock-Up Period Will End on December 15th

Femasys'' lock-up period will end on Wednesday, December 15th. Femasys had issued 2,650,000 shares in its public offering on June 18th. The total size of the offering was

Business Mag | December 12, 2021

Femasys Inc.s Lock-Up Period Will End on December 15th (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY) lock-up period will end on Wednesday, December 15th. Femasys had issued 2,650,000 shares in its public offering on June 18th. The total size of the offering was $34,450,000 based on an initial share price of $13.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following [] The post Femasys Inc.s Lock-Up Period Will End on December 15th (NASDAQ:FEMY) appeared first on ETF Daily News .

ETF Daily News | December 12, 2021

Femasys Inc.s (NASDAQ:FEMY) Lock-Up Period Will Expire on December 15th

Femasys (NASDAQ:FEMY) lock-up period will end on Wednesday, December 15th. Femasys had issued 2,650,000 shares in its IPO on June 18th. The total size of the offering was $34,450,000 based on an initial share price of $13.00. After the end of Femasys lock-up period, restrictions preventing major shareholders and company insiders from selling shares in []

Dakota Financial News | December 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3813 seconds.